Table 1.
Subject characteristics for ART-naïve and ART groups
| |
Total |
ART-naïve |
ART |
P value |
|---|---|---|---|---|
| |
(n = 903) |
(n = 435) |
(n = 468) |
|
| N (%) | N (%) | N (%) | ||
|
Age, yrs, median (IQR) |
33 (29–40) |
32 (28–38) |
35 (30–42) |
< 0.0001 |
|
Female |
697 (77.2) |
331 (76.1) |
366 (78.2) |
0.450 |
|
Education |
|
|
|
|
| No education |
58 (6.4) |
25 (5.8) |
33 (7.1) |
0.654 |
| ≤ Grade 12 |
820 (90.8) |
399 (91.7) |
421 (90.0) |
|
| >Grade 12 |
25 (2.8) |
11 (2.5) |
14 (3.0) |
|
|
Housing density (persons/room), median (IQR) |
2 (1–3) |
2 (1–3) |
1.5 (1–3) |
0.002 |
|
Employment |
|
|
|
|
| Full or part time |
250 (27.7) |
115 (26.4) |
135 (28.9) |
0.791 |
| Unemployed |
648 (71.8) |
317 (72.9) |
331 (70.3) |
|
| Other |
5 (0.6) |
3 (0.7) |
2 (0.4) |
|
|
Current smoker |
136 (15.1) |
75 (17.2) |
61(13.0) |
0.077 |
|
Ever drank alcohol |
426 (47.2) |
226 (52.0) |
200 (42.8) |
0.006 |
|
CD4 count, cells/μl median (IQR) |
289 (184–455) |
224 (153–437) |
318 (222–468) |
<0.0001 |
|
Previous TB |
379 (49.8) |
254 (64.0) |
125 (34.3) |
< 0.001 |
|
Treatment regimens |
|
|
|
|
| d4T 3TC EFV |
- |
- |
238 (51.8) |
|
| d4T 3TC NVP |
- |
- |
169 (36.3) |
|
| AZT 3TC EFV |
- |
- |
11 (2.4) |
|
| AZT 3TC NVP |
- |
- |
45 (9.6) |
|
| Other |
- |
- |
2 (0.4) |
|
|
Duration of treatment (months) |
|
|
|
|
| d4T |
- |
- |
13.0 (8.0-20.0) |
|
| AZT |
- |
- |
12.0 (7.0-18.5) |
|
|
Body composition |
|
|
|
|
| BMI, kg/m2, median (IQR) |
25.2 (22.0 -29.6) |
24.2 (21.4-29.0) |
26.0 (22.9-30.0) |
0.0004 |
| Waist-to-hip ratio, mean ± SD |
0.85 ± 0.07 |
0.84 ± 0.07 |
0.87 ± 0.08 |
< 0.01 |
| Sagittal height, cm, median (IQR) |
19.3 (17.0-22.0) |
18.3 (16.5-21.0) |
19.8 (17.5-22.5) |
<0.0001 |
| Sum of skinfolds, median (IQR) |
108.8 (69.5-158.7) |
103.8 (64.4-164.1) |
111.5 (74.1-153.8) |
0.557 |
| Calf skinfolds, median (IQR) | 14.6 (8.4 – 21.6) | 15.6 (9.3-22.6) | 13.4 (7.8-20.5) | 0.012 |
d4T, Stavudine; AZT,.Zidovudine; 3TC, Lamuvidine; EFV, Efavirenz; NVP, Nevirapine.